IP Library › Granted Patent US 7,795,400
Granted Patent B2
US 7,795,400 · App. 12/489,391 · Granted Sep 14, 2010

PC5 as a factor IX propeptide processing enzyme

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,400
App. No.
12/489,391
Granted
Sep 14, 2010
Kind
B2
Abstract

Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PC5, are provided. In one embodiment PC5 is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid.

Claims (16)

1. A method for producing a mature Factor IX-containing polypeptide from a proprotein of Factor IX (proFIX), or a conjugate thereof, the method comprising:

contacting the proFIX or the conjugate thereof with an effective amount of functional PC5.

2. The method of claim 1 , wherein the proFIX or the conjugate thereof is proFIX.

3. The method of claim 1 , wherein the proFIX or the conjugate thereof is a PEGylated proFIX.

4. The method of claim 1 , wherein the proFIX or the conjugate thereof is a proFIX-FcRn binding partner fusion protein.

5. The method of claim 4 , wherein the proFIX-FcRn binding partner fusion protein comprises a linker connecting proFIX to FcRn binding partner.

6. The method of claim 5 , wherein the proFIX-FcRn binding partner fusion protein is a proFIX-Fc fusion protein.

7. The method of claim 6 , wherein the proFIX-Fc fusion protein comprises a human Fc gamma.

8. The method of claim 6 , wherein the proFIX-FcRn binding partner fusion protein comprises a linker connecting proFIX to Fc.

9. The method of claim 6 , wherein the proFIX-Fc fusion protein is a proFIX-Fc homodimer.

10. The method of claim 6 , wherein the proFIX-Fc fusion protein is a proFIX-Fc monomer-dimer hybrid.

11. The method of claim 1 , wherein the proFIX or the conjugate thereof is a proFIX-albumin fusion protein.

12. The method of claim 11 , wherein the proFIX-albumin fusion protein comprises a linker connecting proFIX to albumin.

13. The method of claim 1 , wherein the proFIX or the conjugate thereof is a proFIX-transferrin fusion protein.

14. The method of claim 13 , wherein the proFIX-transferrin fusion protein comprises a linker connecting proFIX to transferrin.

15. The method of any one of claims 5 , 8 , 12 , or 14 wherein the linker is GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO:16).

Assignments (4)
CHANGE OF NAME Recorded Feb 16, 2017
From: BIOGEN HEMOPHILIA INC.
To: BIOVERATIV THERAPEUTICS INC.
Reel/Frame 041735/0671 →
CHANGE OF NAME Recorded Jan 31, 2017
From: BIOGEN IDEC HEMOPHILIA INC.
To: BIOGEN HEMOPHILIA INC.
Reel/Frame 041578/0743 →
CHANGE OF NAME Recorded Jun 29, 2016
From: SYNTONIX PHARMACEUTICALS, INC.
To: BIOGEN IDEC HEMOPHILIA INC.
Reel/Frame 039206/0091 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2009
From: PETERS, ROBERT T.; BITONTI, ALAN J.
To: SYNTONIX PHARMACEUTICALS, INC.
Reel/Frame 023522/0317 →